Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case, vs. other csDMARD 41% Improvement Relative Risk Case, vs. methotrexate 21% Case, vs. TNF inhibitor 55% c19hcq.org Patel et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective study in the USA Fewer cases with HCQ (p=0.02) Patel et al., Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2022.152108 Favors HCQ Favors control
Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study
Patel et al., Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2022.152108
Patel et al., Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic Diseases: A.., Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2022.152108
Oct 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 11,468 vaccinated rheumatic disease patients, showing lower risk of COVID-19 cases with HCQ/CQ (antimalarial) treatment compared with all other treatments, statistically significant for 6 treatments. This study is excluded in meta analysis: authors only provide multiple results comparing with specific other treatments.
risk of case, 41.2% lower, HR 0.59, p = 0.02, adjusted per study, inverted to make HR<1 favor treatment, HCQ/CQ vs. other csDMARD, multivariable, Cox proportional hazards.
risk of case, 21.3% lower, HR 0.79, p = 0.34, adjusted per study, inverted to make HR<1 favor treatment, HCQ/CQ vs. methotrexate, multivariable, Cox proportional hazards.
risk of case, 54.8% lower, HR 0.45, p = 0.003, adjusted per study, inverted to make HR<1 favor treatment, HCQ/CQ vs. TNF inhibitor, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Patel et al., 26 Oct 2022, retrospective, USA, peer-reviewed, mean age 60.0, 12 authors.
Contact: zswallace@mgh.harvard.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal Pre-proof Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study Naomi J. Patel , Xiaosong Wang , Xiaoqing Fu , Yumeko Kawano , Claire Cook , Kathleen M.M. Vanni , Grace Qian , Emily Banasiak , Emily Kowalski , Yuqing Zhang , Jeffrey A. Sparks , Zachary S. Wallace PII: DOI: Reference: S0049-0172(22)00159-7 https://doi.org/10.1016/j.semarthrit.2022.152108 YSARH 152108 To appear in: Seminars in Arthritis & Rheumatism Please cite this article as: Naomi J. Patel , Xiaosong Wang , Xiaoqing Fu , Yumeko Kawano , Claire Cook , Kathleen M.M. Vanni , Grace Qian , Emily Banasiak , Emily Kowalski , Yuqing Zhang , Jeffrey A. Sparks , Zachary S. Wallace , Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study, Seminars in Arthritis & Rheumatism (2022), doi: https://doi.org/10.1016/j.semarthrit.2022.152108 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Elsevier Inc. All rights reserved. Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study Naomi J. Patel1,4; Xiaosong Wang2, Xiaoqing Fu1; Yumeko Kawano2,4; Claire Cook1,3; Kathleen M.M. Vanni2; Grace Qian2; Emily Banasiak2; Emily Kowalski2; Yuqing Zhang1,3,4; Jeffrey A. Sparks2,4*; Zachary S. Wallace1,3,4,*,# zswallace@mgh.harvard.edu 1 Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Rheumatology Associates, 55 Fruit Street, Boston, MA, 02114, USA 2 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, 60 Fenwood Road, Boston, MA, 02115, USA 3 Clinical Epidemiology Program, Mongan Institute, Department of Medicine, Massachusetts General Hospital, The Mongan Institute, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA 4 Harvard Medical School, Boston, MA * Corresponding author: Zachary S. Wallace, Clinical Epidemiology Program, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, 100 Cambridge Street, 16th Floor, Boston, MA, 02114 * These authors contributed equally to this work (co-last authors). Abstract Objective: Rheumatic disease patients on certain immunomodulators are at increased risk of impaired humoral response to SARS-CoV-2 vaccines. We aimed to identify factors associated with breakthrough infection among patients with rheumatic diseases. Methods: We identified patients with rheumatic diseases being treated with immunomodulators in a large healthcare system who received at least two doses of either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) vaccines or one dose of the Johnson & JohnsonJanssen (J&J) vaccine. We followed patients until SARS-CoV-2 infection, death, or December 15, 2021, when the Omicron variant became dominant in our region. We estimated the association of baseline characteristics with the risk of breakthrough..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit